ArticleBiological procedures online2026
Mechanism of RBM15 in the Immune Escape of Non-small Cell Lung Cancer Cells Via the LncRNA EGFR-AS1/USP3/PD-L1 Axis.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is the most prevalent subtype of lung cancer, with persistently low overall cure and survival rates, largely attributed to tumor immune escape. This study aims to explore the role of RBM15 in the immune escape of NSCLC and provide a potential therapeutic target. Firstly, RBM15, LncRNA EGFR-AS1, PCBP2, USP3, and PD-L1 were detected in NSCLC cells. Peripheral blood mononuclear cells (PBMCs) were co-cultured with NSCLC cells to assess PBMC cytotoxicity, CD8⁺T and CD107a+CD8+T cell proportion, and levels of IFN-γ, IL-10, and IL-2. To verify the mechanism, m6A enrichment on EGFR-AS1 was analyzed. The m6A modification sites on EGFR-AS1 were assayed. The interactions among EGFR-AS1-PCBP2, PCBP2-USP3, and USP3-PD-L1 were detected. We found that RBM15, EGFR-AS1 and PCBP2 were upregulated in NSCLC cells. Mechanistically, RBM15 stabilized EGFR-AS1 through m6A modification, increased the binding of EGFR-AS1 to PCBP2, and promoted USP3 expression. USP3 bound to PD-L1 and inhibited PD-L1 ubiquitination and degradation. In PBMC-NSCLC co-cultures, RBM15 downregulation increased PBMC cytotoxicity, CD8⁺T cell proportion, IFN-γ/IL-2 levels, and decreased IL-10 levels—effects partially reversed by EGFR-AS1 or USP3 overexpression. In conclusion, RBM15 enhances the immune escape of NSCLC through the EGFR-AS1/USP3/PD-L1 axis via m6A modification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.